{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T16:52:23Z","timestamp":1772902343024,"version":"3.50.1"},"posted":{"date-parts":[[2026,3,4]]},"group-title":"Immunology","reference-count":58,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"crossref","award":["T32 DK007745"],"award-info":[{"award-number":["T32 DK007745"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Pollock Center for Research in Inflammatory Bowel Disease"},{"name":"Texas Society of Gastroenterology and Endoscopy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,3,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:p>\n                  Type I interferons (IFN-Is) play a critical role in innate immunity, modulating the host response. While dysregulated IFN-I signaling has been implicated in autoimmune and infectious disorders, its role in inflammatory bowel disease (IBD) remains unclear. In this study, we extensively assessed the function of IFN-I signaling in human IBD and murine models of colitis. Expression of IFN-I signature genes was elevated in patients with active ulcerative colitis as well as multiple murine models of colitis. Single cell RNA sequencing revealed that upregulated IFN-I signature genes were enriched in myeloid cells, which exhibited increased expression of IFN receptors during mucosal inflammation. Mice carrying gain-of-function alleles of\n                  <jats:italic>Ifnar1<\/jats:italic>\n                  , a subunit of IFN-I receptor, showed heightened IFN-I signaling and altered colonic immune homeostasis at baseline, and were more susceptible to experimental colitis. In contrast, postnatal inhibition of IFNAR1, using either an inducible transgenic mouse model or an anti-IFNAR1 blocking antibody, protected against experimental colitis. Taken together, our findings reveal a previously under-recognized pathogenic role of IFN-I in IBD and provide a rationale for therapeutic intervention targeting this pathway.\n                <\/jats:p>","DOI":"10.64898\/2026.03.02.709022","type":"posted-content","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T19:10:24Z","timestamp":1772651424000},"source":"Crossref","is-referenced-by-count":0,"title":["Type I interferon signaling promotes mucosal inflammation in murine models of colitis"],"prefix":"10.64898","author":[{"given":"Jianyi","family":"Yin","sequence":"first","affiliation":[{"name":"Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo","family":"Galicia Pereyra","sequence":"additional","affiliation":[{"name":"Immunology Graduate Program, University of Texas Southwestern Medical Center, Dallas, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Sifuentes-Dominguez","sequence":"additional","affiliation":[{"name":"Division of Pediatric Gastroenterology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8782-3648","authenticated-orcid":false,"given":"Emre E","family":"Turer","sequence":"additional","affiliation":[{"name":"Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ezra","family":"Burstein","sequence":"additional","affiliation":[{"name":"Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA"},{"name":"Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2026030615050565000_2026.03.02.709022v1.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2025.06.044"},{"key":"2026030615050565000_2026.03.02.709022v1.2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032713-120231"},{"key":"2026030615050565000_2026.03.02.709022v1.3","doi-asserted-by":"publisher","DOI":"10.1038\/nri3581"},{"key":"2026030615050565000_2026.03.02.709022v1.4","doi-asserted-by":"crossref","unstructured":"Cohen RH , and Colgan SP . Mucosal Responses to Type II Interferon in IBD. Inflamm Bowel Dis. 2025.","DOI":"10.1093\/ibd\/izaf143"},{"key":"2026030615050565000_2026.03.02.709022v1.5","doi-asserted-by":"crossref","unstructured":"Broggi A , Granucci F , and Zanoni I . Type III interferons: Balancing tissue tolerance and resistance to pathogen invasion. J Exp Med. 2020;217(1).","DOI":"10.1084\/jem.20190295"},{"key":"2026030615050565000_2026.03.02.709022v1.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00826-z"},{"key":"2026030615050565000_2026.03.02.709022v1.7","doi-asserted-by":"publisher","DOI":"10.1038\/nri3787"},{"key":"2026030615050565000_2026.03.02.709022v1.8","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S280953"},{"key":"2026030615050565000_2026.03.02.709022v1.9","doi-asserted-by":"publisher","DOI":"10.1038\/nature06005"},{"key":"2026030615050565000_2026.03.02.709022v1.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.017"},{"issue":"2","key":"2026030615050565000_2026.03.02.709022v1.11","first-page":"125","article-title":"Inflammatory bowel disease pathobiology: the role of the interferon signature","volume":"33","year":"2020","journal-title":"Ann Gastroenterol"},{"issue":"2","key":"2026030615050565000_2026.03.02.709022v1.12","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40120-023-00565-7","article-title":"Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives","volume":"13","year":"2024","journal-title":"Neurol Ther"},{"issue":"9","key":"2026030615050565000_2026.03.02.709022v1.13","first-page":"CD006790","article-title":"Type I interferons for induction of remission in ulcerative colitis","volume":"2015","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"2026030615050565000_2026.03.02.709022v1.14","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.livres.2021.04.001","article-title":"Ulcerative colitis triggered by pegylated interferon alpha-2b in a patient with chronic hepatitis B: A case report and literature review","volume":"5","year":"2021","journal-title":"Liver Res"},{"key":"2026030615050565000_2026.03.02.709022v1.15","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21242"},{"key":"2026030615050565000_2026.03.02.709022v1.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2010.10.007"},{"issue":"11","key":"2026030615050565000_2026.03.02.709022v1.17","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1093\/ecco-jcc\/jjz079","article-title":"Mosaic Tetrasomy 9p Associated With Inflammatory Bowel Disease","volume":"13","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2026030615050565000_2026.03.02.709022v1.18","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3409"},{"key":"2026030615050565000_2026.03.02.709022v1.19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016967"},{"key":"2026030615050565000_2026.03.02.709022v1.20","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200522996"},{"key":"2026030615050565000_2026.03.02.709022v1.21","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201344401"},{"key":"2026030615050565000_2026.03.02.709022v1.22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22928-0"},{"key":"2026030615050565000_2026.03.02.709022v1.23","first-page":"1713424","article-title":"Type I interferons in inflammatory bowel diseases: balancing barrier integrity, repair and inflammation in the intestinal epithelium","volume":"12","year":"2025","journal-title":"Front Med (Lausanne"},{"key":"2026030615050565000_2026.03.02.709022v1.24","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-0273-0"},{"issue":"8","key":"2026030615050565000_2026.03.02.709022v1.25","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s43588-021-00114-y","article-title":"The Inflammatory Bowel Disease Transcriptome and Metatranscriptome Meta-Analysis (IBD TaMMA) framework","volume":"1","year":"2021","journal-title":"Nat Comput Sci"},{"key":"2026030615050565000_2026.03.02.709022v1.26","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gks1215"},{"key":"2026030615050565000_2026.03.02.709022v1.27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10769-x"},{"key":"2026030615050565000_2026.03.02.709022v1.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2013.08.002"},{"key":"2026030615050565000_2026.03.02.709022v1.29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40156-6"},{"key":"2026030615050565000_2026.03.02.709022v1.30","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01680-y"},{"issue":"2","key":"2026030615050565000_2026.03.02.709022v1.31","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jcmgh.2021.04.004","article-title":"Longitudinal Single-Cell Transcriptomics Reveals a Role for Serpina3n-Mediated Resolution of Inflammation in a Mouse Colitis Model","volume":"12","year":"2021","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"2026030615050565000_2026.03.02.709022v1.32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002065"},{"key":"2026030615050565000_2026.03.02.709022v1.33","doi-asserted-by":"publisher","DOI":"10.1002\/emmm.201303236"},{"issue":"10","key":"2026030615050565000_2026.03.02.709022v1.34","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1016\/j.jid.2016.06.608","article-title":"Therapeutic Elimination of the Type 1 Interferon Receptor for Treating Psoriatic Skin Inflammation","volume":"136","year":"2016","journal-title":"J Invest Dermatol"},{"key":"2026030615050565000_2026.03.02.709022v1.35","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000468"},{"key":"2026030615050565000_2026.03.02.709022v1.36","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.04.045"},{"key":"2026030615050565000_2026.03.02.709022v1.37","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2009.090328"},{"key":"2026030615050565000_2026.03.02.709022v1.38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2011.03412.x"},{"key":"2026030615050565000_2026.03.02.709022v1.39","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2018.31"},{"key":"2026030615050565000_2026.03.02.709022v1.40","doi-asserted-by":"crossref","unstructured":"Rodrigues CP , Cal\u00e7ada RR , Arnaud M , Kaltenbach L , Manser M , Scheidegger A , et al. IFNAR1\u207a Neutrophils Orchestrate Chronic Inflammatory Damage Through Mitochondrial Remodeling. bioRxiv. 2025.","DOI":"10.1101\/2025.09.22.677957"},{"key":"2026030615050565000_2026.03.02.709022v1.41","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20171029"},{"key":"2026030615050565000_2026.03.02.709022v1.42","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200215376"},{"key":"2026030615050565000_2026.03.02.709022v1.43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002811"},{"key":"2026030615050565000_2026.03.02.709022v1.44","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20101158"},{"issue":"1","key":"2026030615050565000_2026.03.02.709022v1.45","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jcmgh.2016.09.007","article-title":"Interferon-Alpha Promotes Th1 Response and Epithelial Apoptosis via Inflammasome Activation in Human Intestinal Mucosa","volume":"3","year":"2017","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"2026030615050565000_2026.03.02.709022v1.46","doi-asserted-by":"publisher","DOI":"10.1038\/nature11582"},{"key":"2026030615050565000_2026.03.02.709022v1.47","doi-asserted-by":"crossref","unstructured":"Horesh ME , Martin-Fernandez M , Gruber C , Buta S , Le Voyer T , Puzenat E , et al. Individuals with JAK1 variants are affected by syndromic features encompassing autoimmunity, atopy, colitis, and dermatitis. J Exp Med. 2024;221(6).","DOI":"10.1084\/jem.2023238704302024c"},{"issue":"1","key":"2026030615050565000_2026.03.02.709022v1.48","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s10875-020-00867-7","article-title":"JAK Inhibition in a Patient with X-Linked Reticulate Pigmentary Disorder","volume":"41","year":"2021","journal-title":"J Clin Immunol"},{"key":"2026030615050565000_2026.03.02.709022v1.49","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-017-0042-6"},{"key":"2026030615050565000_2026.03.02.709022v1.50","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaa216"},{"issue":"7","key":"2026030615050565000_2026.03.02.709022v1.51","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/ecco-jcc\/jjaa022","article-title":"Intestinal Epithelial Cells Express Immunomodulatory ISG15 During Active Ulcerative Colitis and Crohn\u2019s Disease","volume":"14","year":"2020","journal-title":"J Crohns Colitis"},{"issue":"5","key":"2026030615050565000_2026.03.02.709022v1.52","doi-asserted-by":"crossref","first-page":"G439","DOI":"10.1152\/ajpgi.00104.2022","article-title":"DNA sensor-associated type I interferon signaling is increased in ulcerative colitis and induces JAK-dependent inflammatory cell death in colonic organoids","volume":"323","year":"2022","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"10","key":"2026030615050565000_2026.03.02.709022v1.53","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1093\/ibd\/izae105","article-title":"Short-Term Use of Upadacitinib in Combination With Biologic Therapy for Inducing Clinical Remission in Patients With Active Inflammatory Bowel Disease","volume":"30","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2026030615050565000_2026.03.02.709022v1.54","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2023-102400"},{"issue":"12","key":"2026030615050565000_2026.03.02.709022v1.55","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1093\/ibd\/izab135","article-title":"Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise","volume":"27","year":"2021","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"2026030615050565000_2026.03.02.709022v1.56","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1097\/MIB.0000000000000758","article-title":"Actual Usage and Quality of Experimental Colitis Models in Preclinical Efficacy Testing: A Scoping Review","volume":"22","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2026030615050565000_2026.03.02.709022v1.57","doi-asserted-by":"publisher","DOI":"10.1097\/01.MIB.0000187582.90423.bc"},{"key":"2026030615050565000_2026.03.02.709022v1.58","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2017.044"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.03.02.709022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T23:05:22Z","timestamp":1772838322000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.64898\/2026.03.02.709022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":58,"URL":"https:\/\/doi.org\/10.64898\/2026.03.02.709022","relation":{},"subject":[],"published":{"date-parts":[[2026,3,4]]},"subtype":"preprint"}}